Figure 7.

SDE combination increases the anti-tumor activity of paclitaxel, both in culture and in mice. (A,B) MDAH2774 and SKOV3 cells were treated with paclitaxel together with SDE (sunitinib, dasatinib, and everolimus) combinations, at the indicated concentrations. Cell viability was determined 72 h later. (C) CI was calculated using the Chou–Talalay method. Results are representative of at least three preparations. (D) MDAH2774 cells were implanted into the peritoneal cavities of female athymic nude mice. Tumors were treated with vehicle, paclitaxel (10 mg/kg, twice/week), SDE combination (sunitinib [40 mg/kg daily], dasatinib [15 mg/kg daily], everolimus [5 mg/kg, 3 times/week]), or combination of all four. Data represents mean ± SD (n = 6–10). **, p < 0.005; ****, p < 0.0001; combination vs. vehicle, or SDE, or paxlitexel. Mice were euthanized four weeks later. The tumor nodules throughout the peritoneal cavity were excised and weighed.